New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:03 EDTCLSNCelsion announces data supporting development of ThermoDox
Celsion announced that data supporting the development of ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound were presented at the International Symposium on Therapeutic Ultrasound. Mark Dewhirst, D.V.M., Ph.D. presented data demonstrating the potential of ThermoDox plus HIFU to maximize drug delivery to the targeted tumor site. Celsion is exploring the potential of ThermoDox in combination with HIFU as a non-invasive treatment for a variety of cancers, including pancreatic cancer, Glioblastoma Multiforme, metastatic liver cancer, and breast cancer.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
08:08 EDTCLSNCelsion's ThermoDox for liver cancer shows positive overall survival data
Subscribe for More Information
July 24, 2014
08:18 EDTCLSNCelsion's Thermodox for breast cancer shows positive Phase 2 results
Celsion announced positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer. 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses, 2 partial responses and 1 patient with stable disease. These data are consistent with the previously reported positive Phase 1 data in RCWBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use